DBS downgrades Medtecs to 'hold' after 'missed expectations' for 1Q21
Lim Hui Jie • • 2 min read
Despite a stellar y-o-y performance, DBS Group Research has downgraded Medtecs to a "hold" rating. Find out why.
Follow us on Facebook and join our Telegram channel for the latest updates.
DBS Group Research’s Woon Bing Yong and Ling Lee Keng have downgraded their rating for Medtecs International from ‘buy’ to ‘hold’, as well as lowering their target price to 92 cents from $1.25.
They cited a “disappointing” performance for 1QFY2021, noting the decline in revenue to US$42.2 million ($55.87 million).
Never miss out on important financial news and get daily updates today
×
Download The Edge Singapore App
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
